PF-AtlasКлинические испытания › NCT02029521

Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients

Oral reduced l-glutathione · Не указано

ID реестра
NCT02029521
Фаза
Не указано
Статус
Завершено
Препарат / вмешательство
Oral reduced l-glutathione
Спонсор
Clark Bishop
Начало
2011-03
Набор участников
47
Центры
1

Об исследовании

Many individuals with cystic fibrosis experience growth failure. The reasons are not clear, but inflammation of the gut in these patients seems to be one important reason. Glutathione is important to normal function of the intestine and lungs. Glutathione functions to decrease inflammation and to thin mucus. However, in cystic fibrosis, glutathione gets trapped inside of cells, so it cannot travel to the surface of the cells and perform its proper function. Moreover, glutathione has been shown to improve nutritional status in patients with AIDS and cancer. Investigators hypothesize that supplementation of oral glutathione to pediatric individuals with cystic fibrosis could improve growth failure.

Открыть NCT02029521 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT02029521 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.